188 related articles for article (PubMed ID: 24061041)
21. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
22. Metastatic RCC: moving towards a chronic disease.
Escudier B
Oncology (Williston Park); 2012 Mar; 26(3):304, 306. PubMed ID: 22545316
[No Abstract] [Full Text] [Related]
23. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
24. Novel targets and therapies for metastatic renal cell carcinoma.
Feldman DR; Motzer RJ
Oncology (Williston Park); 2006 Dec; 20(14):1745-53; discussion 1756. PubMed ID: 17263126
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.
Mihaly Z; Sztupinszki Z; Surowiak P; Gyorffy B
Curr Cancer Drug Targets; 2012 Sep; 12(7):857-72. PubMed ID: 22515521
[TBL] [Abstract][Full Text] [Related]
26. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
27. Treatment of elderly patients with metastatic renal cell carcinoma.
Zanardi E; Grassi P; Cavo A; Verzoni E; Maggi C; De Braud F; Boccardo F; Procopio G
Expert Rev Anticancer Ther; 2016; 16(3):323-34. PubMed ID: 26654225
[TBL] [Abstract][Full Text] [Related]
28. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK; Mughal TI; Rini BI
Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
[TBL] [Abstract][Full Text] [Related]
29. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.
Tsimafeyeu I; Bratslavsky G
Oncology; 2015; 88(6):321-31. PubMed ID: 25678187
[TBL] [Abstract][Full Text] [Related]
31. New insights into the management of renal cell cancer.
Pécuchet N; Fournier LS; Oudard S
Oncology; 2013; 84(1):22-31. PubMed ID: 23076127
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
33. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy for sarcomatoid renal cell carcinoma.
Pagliaro LC; Tannir N; Sircar K; Jonasch E
Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.
Pal SK; Singh P; Vogelzang NJ
Clin Genitourin Cancer; 2015 Aug; 13(4):257-260. PubMed ID: 25160519
[No Abstract] [Full Text] [Related]
37. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
38. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
39. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
40. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
Amato R
Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
